The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 58, Issue 10, 2017, Pages 2419-2425

  Vilia, Maria Giovanna ^a   Fonte, Eleonora ^a   Veliz Rodriguez, Tania ^a   Tocchetti, Marta ^a   Ranghetti, Pamela ^a   Scarfò, Lydia ^a,b   Papakonstantinou, Nikos ^c,d   Ntoufa, Stavroula ^c,d   Stamatopoulos, Kostas ^c,d   Ghia, Paolo ^a,b   Muzio, Marta ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c INFORMATION TECHNOLOGIES INSTITUTE   (Greece)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

Azacytidine; chronic lymphocytic leukemia; SIGIRR; TIR8; toll interleukin 1 receptor 8; Toll like receptors

Indexed keywords

AZACITIDINE; CD19 ANTIGEN; INHIBITOR PROTEIN; MEMBRANE RECEPTOR; MESSENGER RNA; PROTEIN; TOLL INTERLEUKIN 1 RECEPTOR 8; TOLL LIKE RECEPTOR 10; TRANSCRIPTION FACTOR RELA; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; INTERLEUKIN 1 RECEPTOR; SIGIRR PROTEIN, HUMAN; SIGIRR PROTEIN, MOUSE;

ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CANCER PROGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; JURKAT CELL LINE; LEUKEMIA CELL LINE; LEUKEMOGENESIS; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; ANIMAL; DISEASE MODEL; GENETICS; INFLAMMATION; METABOLISM;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DISEASE MODELS, ANIMAL; DNA METHYLATION; HUMANS; INFLAMMATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; RECEPTORS, INTERLEUKIN-1;

EID: 85014482858     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428194.2017.1295142     Document Type: Article

References (21)

1. Sutton LA, Rosenquist R., The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia. Semin Cancer Biol. 2015;34:22–35.
2. Isaza-Correa JM, Liang Z, van den Berg A, et al. Toll-like receptors in the pathogenesis of human B cell malignancies. J Hematol Oncol. 2014;7:499–410.
3. Muzio M, Bertilaccio MTS, Simonetti G, et al. The role of toll-like receptors in chronic B-cell malignancies. Leuk Lymphoma. 2009;50:1573–1580.
4. Fonte E, Apollonio B, Scarfò L, et al. In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors. Clin Cancer Res. 2013;19:367–379.
5. Frenquelli M, Muzio M, Scielzo C, et al. MicroRNA and proliferation control in chronic lymphocytic leukemia:functional relationship between miR-221/222 cluster and p27. Blood. 2010;115:3949–3959.
6. Ntoufa S, Vardi A, Papakonstantinou N, et al. Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors. Mol Med. 2012;18:1281–1291.
7. Muzio M, Scielzo C, Bertilaccio MTS, et al. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol. 2009;144:507–516.
8. Riva F, Bonavita E, Barbati E, et al. TIR8/SIGIRR is an interleukin-1 receptor/toll like receptor family member with regulatory functions in inflammation and immunity. Front Immun. 2012;3:322.
9. Xiao H, Gulen MF, Qin J, et al. The toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity. 2007;26:461–475.
10. Garlanda C, Riva F, Veliz T, et al. Increased susceptibility to colitis-associated cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family. Cancer Res. 2007;67:6017–6021.
11. Bertilaccio MTS, Simonetti G, Dagklis A, et al. Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models. Blood. 2011;118:660–669.
12. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456.
13. Apollonio B, Bertilaccio MTS, Restuccia U, et al. From a 2DE-gel spot to protein function:lesson learned from HS1 in chronic lymphocytic leukemia. J Vis Exp. 2014;e51942–e51942.
14. Arvaniti E, Ntoufa S, Papakonstantinou N, et al. Toll-like receptor signaling pathway in chronic lymphocytic leukemia:distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. Haematologica. 2011;96:1644–1652.
15. Kadota C, Ishihara S, Aziz MM, et al. Down-regulation of single immunoglobulin interleukin-1R-related molecule (SIGIRR)/TIR8 expression in intestinal epithelial cells during inflammation. Clin Exp Immunol. 2010;162:348–361.
16. Stacchini A, Aragno M, Vallario A, et al. MEC1 and MEC2:two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res. 1999;23:127–136.
17. Gutierrez A, Tschumper RC, Wu X, et al. LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood. 2010;116:2975–2983.
18. Zhu YY, Su Y, Li ZG, et al. The largely normal response to Toll-like receptor 7 and 9 stimulation and the enhanced expression of SIGIRR by B cells in systemic lupus erythematosus. PLoS One. 2012;7:e44131.
19. Fonte E, Agathangelidis A, Reverberi D, et al. Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation. Haematologica. 2015;100:1460–1468.
20. Kanduri M, Cahill N, Göransson H, et al. Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood. 2010;115:296–305.
21. Malik A, Shoukier M, Garcia-Manero G, et al. Azacitidine in fludarabine-refractory chronic lymphocytic leukemia:a phase II study. Clin Lymph Myeloma Leuk. 2013;13:292–295.